PLATELET ACTIVITY IN THE CHRONIC SCHIZOPHRENIC PATIENTS DURING ATTACKS OUTCOME AND REMISSION DEVELOPMENT

Cover Page

Abstract


The purpose of this work was to evaluate the degree of activation of platelets chronically schizophrenic patients with paroxysmal course of the disease during outcome from the attack of disease or in process of forming of the remission. Platelets in platelet-rich-plasma (PRP) and after PRP gel-filtration through the column with Sepharose CL-2B taken from the ulnar vein of males with chronic schizophrenia during outcome from the attack of disease or in process of forming of the remission were measured. Patients were investigated on the peak of the disease attack (visit 1), at the stage of significant improvement of clinical state (visit 2), and at the stage of stable drug-induced remission (visit 3). Platelet quantities in PRP prepared by centrifugation are equal in patients in visits 1, 2 or 3. These platelets quantities are much less than similar platelet quantities in healthy individuals matched in age. The additional decreases of platelet quantities were found after the elution of PRP platelets from the column with Sepharose CL-2B. These additional platelet quantity losses are increased from visit 1 to visit 3. Such losses of cells indicate decrease in their resistance to various influences, their activation in spite of remission development in this group of patients.

 


O. S. Brusov

Mental Health Research Center of the Russian Academy of Medical Sciences, Moscow, Russian Federation

Author for correspondence.
Email: oleg_brusov@mail.ru

Russian Federation MD, chief of the clinical biochemistry laboratory of the Federal State Budgetary Institution «Mental Health Research Center» of RAMS. Address: bld. 16, build. 3, 2, Zagorodnoye Route, Moscow, 117152; tel.: (495) 952-91-41

G. P. Zlobina

Mental Health Research Center of the Russian Academy of Medical Sciences, Moscow, Russian Federation

Email: zlobina2000@mail.ru

Russian Federation MD, senior research scientist of the clinical biochemistry laboratory of the Federal State Budgetary Institution «Mental Health Research Center» of RAMS. Address: bld. 16, build. 3, 2, Zagorodnoye Route, Moscow, 117152; tel.: (495) 952-91-41

  1. Yamamoto H., Gurney M.E. Human platelets contain brain-derived neurotrophic factor. J. Neurosci. 1990; 10 (11): 3469–78.
  2. Yeaman M.R., Tang Y.Q., Shen A.J. et al. Purification and in vitro activities of rabbit platelet microbicidal proteins. Infect. Immun. 1997; 65 (3): 1023–1031.
  3. Zarbock A., Polanowska-Grabowska R.K., Ley K.. Platelet-neutrophil-interactions:linking hemostasis and inflammation. Blood Rev. 2007; 2 (3): 99–111.
  4. Klinger M.H., Jelkmann W. Role of blood platelets in infection and inflammation. J. Interferon Cytokine Res. 2002; 22 (9): 913–922.
  5. Strous R.D., Shoenfeld Y. Schizophrenia, autoimmunity and immune system degradation: A comprehensive model updated and revisited. J. Autoimm. 2006; 27 (2): 71–80.
  6. Yeaman M.R., Bauer A.S. Antimicrobial peptides from platelets. Drug Resist. Updates. 1999; 2 (2): 116–126.
  7. Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., Nawa H. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res. 2002; 110 (3): 249–257.
  8. Shcherbakova I.V., Kaleda V.G.,Barkhatova A.N., Klyushnik T. P. Markers of endothelial dysfunction in attack-like progressive schizophrenia. Zhurnal nevrologii i psikhiatrii = Journal of Neurology and Psychiatry. 2005; 105(3): 43–46.
  9. Belsham B. Glutamate and its role in psychiatric illness. Hum. Psychopharmacol. 2001; 16 (2): 139–146.
  10. Zlobina G.P., Brusov O.S., Morozova M.A., Beniashvili A.G. Properties and state of separation of platelets in schizophrenic patients. Zhurnal nevrologii i psikhiatrii = Journal of Neurology and Psychiatry. 2009; 109(10): 47–50.
  11. Leucht S., Beitinger R., Kissling W. On the concept of remission in schizophrenia. Psychopharmacol. 2007; 194 (4): 453–461.
  12. Rossi A., Bagala A., Del Curatolo V., Scapati F., Bemareggi M.M., Giustra M.G. Remission in schizophrenia: one-year italian prospective study of risperidone long-acting injectable (RLA) in patients with schizophrenia or schizoaffective disorder. Hum. Psychopharmacol. 2009; 24 (7): 574–583.
  13. Kiktenko A.I., Zlobina G.P.,Shchurin M.R., Kleshchinov V.N. Influence of different methods of isolation of platelets on the surface structure and biochemical parameters serotonin sistmy these cells. Byulleten' eksperimental'noi biologii = Bulletin of Experimental Biology. 1991; 112(11): 485–488.
  14. Shitikova А.S. Trombotsitarnyy gemostaz. [Thrombocytic Hemostasis]. Saint-Petersburg, SPbGMU, 2000. 227 p.
  15. Uzbekov M.G., Smolina N.V., Misionzhnik E.Yu., Molodetskikh A.V., Dobretsov G.E., Grizunov Yu.A. Zhurnal nevrologii i psikhiatrii = Journal of Neurology and Psychiatry. 2008; 108(5): 67–70.

Views

Abstract - 15

PDF (Russian) - 1

Cited-By


PlumX



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.